logo
ResMed's Fifth Annual Global Sleep Survey Reveals a World Struggling with Poor Sleep

ResMed's Fifth Annual Global Sleep Survey Reveals a World Struggling with Poor Sleep

Yahoo28-02-2025
New insights from 30,026 people across 13 markets show the global scale of poor sleep and its impact on health, work, and relationships
7 out of 10 employed respondents have called in sick at least once in their career due to poor sleep.
18% of couples reported sleeping in separate rooms due to snoring and restlessness.
Women report fewer quality sleep nights and more difficulties falling asleep than men.
SAN DIEGO, Feb. 26, 2025 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD), a global health technology leader focused on sleep, breathing, and care delivered in the home, today unveiled the findings of its fifth annual Global Sleep Survey. With insights from 30,026 respondents across 13 markets, the study underscores a widespread global sleep crisis, with people losing an average of nearly three nights of restorative sleep each week.
Despite a trend towards growing awareness of sleep's importance, many continue to suffer in silence and remain trapped in a cycle of exhaustion. The research reveals that nearly one in four (22%) respondents choose to just live with poor sleep rather than seek help. With poor sleep found to impact our lives, from work1, to relationships2, and mental health, there is an urgent need for increased awareness and action on sleep health.
A World Without Rest
About one-third of survey respondents report difficulty falling or staying asleep three or more times per week, citing stress (57%), anxiety (46%), and financial pressures (31%) as primary disruptors. While well-rested individuals experience improved mood, concentration, and productivity, those struggling with poor sleep report excessive daytime sleepiness, irritability, and difficulty concentrating. Yet few take proactive steps to improve their sleep health:
89% of respondents believe sleep makes them feel better about themselves, but only 24% would take immediate action to address sleep issues.
22% globally, and up to 41% in Australia, chose to 'just live with' poor sleep.
45% do not track their sleep, missing valuable insights that could improve sleep quality.
'Sleep is as vital to health as diet and exercise, yet millions struggle in silence,' said Carlos M. Nunez, M.D., ResMed's Chief Medical Officer. 'This research highlights an urgent gap in awareness and action—one that needs immediate attention, to improve global health outcomes.'
Poor Sleep: The Hidden Drain on Workplace Productivity
Quality sleep directly impacts workplace performance, but many employees struggle due to sleep deprivation:
A staggering 71% of employed respondents globally have called in sick due to poor sleep at least once in their career, with the highest rates in India (94%), followed by China (78%), Singapore (73%), and the U.S. (70%).
Nearly half (47%) of the workforce surveyed feel that their sleep health isn't a priority for their employers, presenting an opportunity for employer initiatives to encourage healthy sleep habits.
Bedtime Blues: Sleep Impacts Relationships
Responses from the survey suggest that sleep may play an important role in the health of our relationships:
18% of couples permanently opt for a 'sleep divorce,' choosing to sleep apart due to snoring and restlessness.
Among those who sleep separately, 31% reported improved relationships, while 30% feel theirs have worsened.
Sleep separation also impacts intimacy — 28% say their sex life has improved, while 22% report the opposite.
Sleep Quality Isn't Equal Across Genders
Women experience poorer sleep quality than men:
Women report fewer nights of quality sleep than men (3.83 nights vs. 4.13 nights) per week.
38% of women struggle to fall asleep compared to 29% of men.
Hormonal changes—particularly menopause—are a significant but often overlooked factor affecting sleep, with 44% of menopausal women reporting difficulty falling asleep at least three times per week, compared to 33% of non-menopausal women.
Take Action on Sleep Health
'Chronic poor sleep impacts our relationships, workplace productivity, and increases the risk of cognitive decline, mood disorders, and serious health conditions like heart failure and stroke,' added Dr. Nunez. 'For individuals with untreated or poorly managed sleep apnea, these risks are even greater. That's why talking with a doctor about treating disrupted sleep is important.'
Are you getting enough sleep? Read the full 2025 Global Sleep Survey to learn more about the trends impacting the way we sleep. To assess your sleep health, take our sleep assessment.
Survey MethodologyResMed commissioned a survey of 30,026 individuals in the United States (5,000), China (5,000), India (5,000), United Kingdom (2,000), Germany (2,004), France (2,001), Australia (1,501), Japan (1,500), Korea (1,500), Thailand (1,519), New Zealand (1,000), Singapore (1,000), and Hong Kong (1,001). The samples within each country were representative of the population's gender and age breakdowns. The survey was fielded by PureSpectrum from 12 to 28 December 2024.
About ResMedAt ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.
Contacts
For media628-278-6471news@resmed.com
For investors+1 858.836.5000investorrelations@resmed.com
1 Routinely assessing patients' sleep health is time well spent, Jean-Philippe Chaput, Judy Shiau, Preventive Medicine Reports Volume 14, June 2019, 1008512 Gordon AM, Chen S. The role of sleep in interpersonal conflict: Do sleepless nights mean worse fights? Social Psychological and Personality Science. 2014;5(2):168–175
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Viking Therapeutics stock falls 37% on high dropout rate in obesity trial
Viking Therapeutics stock falls 37% on high dropout rate in obesity trial

Yahoo

time29 minutes ago

  • Yahoo

Viking Therapeutics stock falls 37% on high dropout rate in obesity trial

-- Viking Therapeutics (NASDAQ:VKTX) stock plunged as much as 37% Tuesday after revealing results from its Phase 2 VENTURE-Oral Dosing trial for its oral obesity treatment, while Eli Lilly (NYSE:LLY) shares gained 1.5% as analysts pointed to competitive advantages. The trial demonstrated that Viking's oral tablet formulation of VK2735, a dual GLP-1 and GIP receptor agonist, met its primary endpoint with patients losing up to 12.2% of body weight after 13 weeks compared to 1.3% for placebo. Despite the weight loss efficacy, the 28% treatment discontinuation rate among patients receiving VK2735 versus 18% for placebo raised significant concerns among investors and analysts. Mizuho analyst Jared Holz highlighted competitive disadvantages compared to Eli Lilly's offerings: "Data look inferior to LLY on almost all metrics and the thing to consider here is that patients discontinued at such a high rate over 13-weeks vs. LLY in the mid 20% range --- but over 72-weeks; A much longer trial, and therefor LLY looks far better head-to-head. This probably shutters hope for VKTX a bigtime player in the oral obesity market over the near to medium term." JPMorgan (NYSE:JPM) analyst Hardik Parikh offered a more balanced view, noting, "In 13 weeks, the three highest-dosing arms of 60/90/120mg showed avg pbo-adj weight loss of ~7.5%, 10%, 11%, which we think is very strong compared with other orals in development. Tolerability overall was manageable, but it was worse than we expected based on the ph1 performance." Parikh added that while the adverse event profile wasn't as clean as in Phase 1 trials, "we still think oral vk-2735 offers strong efficacy with a manageable tolerability profile." Viking reported that 99% of gastrointestinal-related adverse events were mild or moderate. The company also highlighted an exploratory maintenance dosing arm showing weight loss could be maintained at lower doses. The major adverse events included vomiting rates of 20-35% in the three highest dose arms compared to about 10% for placebo, and nausea rates of approximately 58% for patients on treatment versus 48% for placebo. Related articles Viking Therapeutics stock falls 37% on high dropout rate in obesity trial Tesla robotaxi trial impresses, pricing power clear: William Blair Palo Alto Networks gains after strong earnings and Bank of America upgrade

Rachelle Ramiro Breaks Down Energy, Clarity, and Control on The Health is A Skill Podcast with Todd Vande Hei
Rachelle Ramiro Breaks Down Energy, Clarity, and Control on The Health is A Skill Podcast with Todd Vande Hei

Yahoo

timean hour ago

  • Yahoo

Rachelle Ramiro Breaks Down Energy, Clarity, and Control on The Health is A Skill Podcast with Todd Vande Hei

In this episode of Health is a Skill, Rachelle Ramiro shares how catching multiple myeloma early led to deeper self-awareness—and powerful healing tools like HBOT, exosomes, and radical self-care. Todd Vande Hei with guest Rachelle Ramiro on The Health is a Skill Podcast Beverly Hills California, Aug. 19, 2025 (GLOBE NEWSWIRE) -- On this new episode of Health is a Skill, host Todd Vande Hei welcomes Rachelle Ramiro, founder of CEO2 Health, for a revealing conversation about how a life-changing diagnosis reshaped her relationship with time, energy, and well-being. Diagnosed with multiple myeloma in her early 30s, Ramiro chose to take a proactive, multi-dimensional approach to healing. Speaking from inside a hyperbaric oxygen chamber, she details how early detection, unconventional therapies, and consistent recovery practices helped her normalize her labs, regain vitality, and stay fully engaged in both work and life. Key topics from the conversation include: Listening to your body: How Ramiro caught signs of cancer before her doctors did—beginning with elevated heart rate and night sweats. Hyperbaric oxygen therapy (HBOT): Why it became her foundation for lowering inflammation, improving sleep, and speeding recovery. Cutting-edge treatments: How exosomes, NAD+, and infrared saunas supported her immunity, cognitive clarity, and resilience. The danger of comfort: Why today's culture of ease is quietly undermining physical and mental health, and how embracing discomfort can heal. Reframing health: From cold plunges to meditation, Ramiro shares how discomfort, presence, and gratitude transformed her mindset and daily energy. Ramiro says, 'At one point, I couldn't even walk because of the pain. But after starting therapies like exosomes, I felt hopeful, mobile, and even joyful. I'm walking in Italy today because I chose to invest in my wellness.' The discussion also explores the growing role of mobile wellness: CEO2 Health now delivers hyperbaric oxygen therapy across homes, offices, events, and luxury spaces through portable chambers and custom installations. To learn more about personalized recovery and mobile hyperbaric therapy, visit About Health Is a SkillHealth is a Skill is a Los Angeles-based podcast hosted by Todd Vande Hei, CEO of Stark Health. Each episode blends scientific insight, personal stories, and actionable habits to show how optimizing healthspan can transform every decade of life. Media Communications: adamtorres@ Attachment Todd Vande Hei with guest Rachelle Ramiro on The Health is a Skill PodcastError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial
Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial

Yahoo

timean hour ago

  • Yahoo

Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial

Addition of Tuspetinib (TUS) to Venetoclax (VEN) and Azacitidine (AZA) is being developed as safe and mutation agnostic frontline therapy for AML Addition of TUS to VEN+AZA improves response rates; 100% CR/CRh at 80 mg and 120 mg Addition of TUS to VEN+AZA improves MRD-negativity rates; 78% among responders 100% CR/CRh in FLT3 wildtype AML, representing 70% of AML population 100% CR/CRh and MRD-negativity rates in TP53, RAS and FLT3-ITD mutated AML Broad spectrum activity and excellent safety profile continue at 120 mg dose to date SAN DIEGO and TORONTO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ('Aptose' or the 'Company') (OTC: APTOF, TSX: APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed AML, today provided a data update from the Phase 1/2 TUSCANY trial in newly diagnosed AML. The trial was initiated in December 2024, and the growing body of positive data includes the recently completed third cohort of 120 mg TUS in the TUS+VEN+AZA triplet therapy. Data to date from ten (10) patients across all three cohorts, 40 mg, 80 mg or 120 mg TUS dose in TUS+VEN+AZA, support the use of TUS with standard of care treatment across all AML populations, including those carrying mutations that are the most difficult to treat and those with mutated and unmutated (wildtype) FLT3 genes. The TUS+VEN+AZA triplet is being developed as a safe and well-tolerated mutation agnostic frontline therapy to treat large, mutationally diverse populations of newly diagnosed AML patients who are ineligible to receive induction chemotherapy. At the 120 mg TUS dose level in combination with VEN+AZA, as with the prior reported 40 mg and 80 mg TUS dose cohorts, no significant safety concerns or dose limiting toxicities (DLTs) have been observed in the TUSCANY trial, including no prolonged myelosuppression in Cycle 1 of subjects in remission, no reports of drug-related QTc prolongation or differentiation syndrome (DS), and no treatment-related deaths. Nine out of ten dosed patients remain on study across all dose cohorts and enrollment is being advanced to the 160 mg TUS dose level following the Cohort Safety Review Committee (CSRC) meeting. 'We already have data from three different TUS dose levels in the TUSCANY trial, and the data continue to strengthen at higher doses of TUS and over time. We are building a strong case for TUS+VEN+AZA as a triplet frontline therapy of choice to address a broad AML population, including subgroups with the most adverse of mutations,' said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer of Aptose. Data highlights: Comparison of CR/CRh1 Response rates2-5: VEN+AZA2 TUS+VEN+AZA All subjects 65% 90% (9/10) NPM1-mutant 67% 100% (2/2) FLT3-ITD 61% 100% (2/2) TP53-mutant 52% 100% (2/2) Comparison of MRD-negativity6 rates among All Subjects and among CR/CRh Responders3: VEN+AZA2,3 TUS+VEN+AZA Among All Subjects 23.4% 70% (7/10) Among CR/CRh Responders 40.9% 78% (7/9) Comparison of MRD-negativity rates among more difficult-to-treat Patient Subpopulations defined as Lower Benefit (TP53-mutated) and Intermediate Benefit (FLT3-ITD or RAS-mutated) relative to VEN+AZA5: VEN+AZA3,5 TUS+VEN+AZA Intermediate Benefit 27.9% 100% (3/3) Lower Benefit 14.5% 100% (2/2) TUS+VEN+AZA - CR/CRh and MRD-negativity rates among Subjects with Adverse Mutations: TP53, FLT3-ITD, RAS mutations: Achieved CR/CRh and MRD-negativity 100% (5/5) 'As illustrated in the data highlights, the addition of TUS to VEN+AZA appears to boost response rates and MRD-negativity while maintaining favorable safety and tolerability,' said Rafael Bejar, M.D., Ph.D., Chief Medical Officer of Aptose, 'and the 100% CR/CRh and 100% MRD-negativity rates among the five biallelic TP53-mutant, FLT3-ITD, and RAS-mutant AML cases are exciting to see, as this can correlate with longer overall survival. We have observed a trend towards achieving CRs more quickly at the higher dose levels, so we are keen to see the activity as we advance into the 160 mg TUS dose cohort.' Key messages: Addition of TUS to VEN+AZA demonstrates excellent CR/CRh rates 100% CR/CRh among all subjects treated at 80 mg and 120 mg TUS dose levels Appear to be achieving CR earlier with 120 mg TUS than with 40 mg or 80 mg Addition of TUS to VEN+AZA demonstrates excellent MRD-negativity rates MRD-negativity in 7 of 9 (78%) already achieved in patients who responded to therapy Expect patient survival to be extended with continued long-term treatment Excellent safety and well tolerated with no dose-limiting toxicities (No DLT) at completed dose levels Broad-spectrum activity including patients with adverse TP53, RAS and FLT3-ITD mutations No loss of MRD-negativity observed to date, including in one patient with over 7 months of follow up MRD-negativity and remissions continue to mature over time on therapy No relapses reported to date and no treatment related deaths The only non-responder was a patient at the initial TUS dose level (40 mg) that did not achieve TUS exposures previously associated with response Additional data are included in the new Aptose corporate presentation here. TUSCANY: TUS+VEN+AZA Triplet Phase 1/2 Study The tuspetinib-based TUS+VEN+AZA triplet therapy is being advanced in the TUSCANY Phase 1/2 trial with the goal of creating an improved frontline therapy for newly diagnosed AML patients that is active across diverse AML populations, durable, and well tolerated. The TUSCANY triplet Phase 1/2 study, being conducted at 10 leading U.S. clinical sites by elite clinical investigators, is designed to test various doses and schedules of TUS in combination with standard dosing of AZA and VEN for patients with AML who are ineligible to receive induction chemotherapy. A convenient, once daily oral agent, TUS is being administered in 28-day cycles. Multiple U.S. sites are enrolling in the TUSCANY trial with anticipated enrollment of 18-24 patients by late 2025. Data will be released as it becomes available. More information on the TUSCANY Phase 1/2 study can be found on (here). About Aptose Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's lead clinical-stage, oral kinase inhibitor tuspetinib (TUS) has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. For more information, please visit Forward Looking Statements This press release may contain forward-looking statements within the meaning of Canadian and U.S. securities laws, including, but not limited to, statements relating to the therapeutic potential and safety profile of tuspetinib (including the triplet therapy) and its clinical development, the anticipated enrollment rate in the TUSCANY trial and the timing thereof, as well as statements relating to the Company's plans, objectives, expectations and intentions and other statements including words such as 'continue', 'expect', 'intend', 'will', 'should', 'would', 'may', and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others: our ability to obtain the capital required for research and operations and to continue as a going concern; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; inability of new manufacturers to produce acceptable batches of GMP in sufficient quantities; unexpected manufacturing defects; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled 'Risk Factors' in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein. For further information, please contact: Aptose Biosciences PietropaoloCorporate Communications & Investor Relations201-923-2049spietropaolo@ 1 Complete Response / Complete Response with Partial Hematological Recovery2 DiNardo et al. New England Journal of Medicine, August 2020; Volume 383(7):617-629.3 Pratz et al. Journal of Clinical Oncology, December 2021; Volume 40 (8):855-865.4 Othman et. al. Blood Neoplasia; September 2024; Volume 1 (3):1-11.5 Döhner et. al. Blood. 2024 November 21;144(21):2211-2222.6 MRD-negative indicates that the amount of Measurable Residual Disease, as assessed by central flow cytometry, is such that the proportion of leukemic cells in a bone marrow sample falls below <0.1%Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store